These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Thrombolytic therapy in canine pulmonary embolism. Comparative effects of urokinase and recombinant tissue plasminogen activator. Prewitt RM, Hoy C, Kong A, Gu SA, Greenberg D, Cook R, Chan SM, Ducas J. Am Rev Respir Dis; 1990 Feb; 141(2):290-5. PubMed ID: 2105682 [Abstract] [Full Text] [Related]
3. Life-threatening pulmonary embolism with right-sided heart thrombus. Rapid recovery with recombinant tissue plasminogen activator. d'Ivernois C, Le Metayer P, Fischer B, Haissaguerre M, Warin JF. Chest; 1994 Apr; 105(4):1291-2. PubMed ID: 8162778 [Abstract] [Full Text] [Related]
4. Recombinant tissue-type plasminogen activator versus a novel dosing regimen of urokinase in acute pulmonary embolism: a randomized controlled multicenter trial. Goldhaber SZ, Kessler CM, Heit JA, Elliott CG, Friedenberg WR, Heiselman DE, Wilson DB, Parker JA, Bennett D, Feldstein ML. J Am Coll Cardiol; 1992 Jul; 20(1):24-30. PubMed ID: 1607532 [Abstract] [Full Text] [Related]
5. Value of transthoracic echocardiography in therapy regimens evaluation in pulmonary embolism. Zhu L, Wang C, Yang Y, Wu Y, Zhai Z, Dai H, Pang B, Tong Z. J Thromb Thrombolysis; 2008 Dec; 26(3):251-6. PubMed ID: 17705052 [Abstract] [Full Text] [Related]
17. [Safe dose rTPA for massive pulmonary embolism associated with high bleeding risk: a case report and review of the literature]. Mele M, Mele A, La Torre PP, Cannone M. G Ital Cardiol (Rome); 2014 Apr 03; 15(4):240-3. PubMed ID: 24873813 [Abstract] [Full Text] [Related]